Navigation Links
Enzyme offers new therapeutic target for cancer drugs
Date:6/21/2012

Researchers at the University of California, San Diego School of Medicine have uncovered a new signal transduction pathway specifically devoted to the regulation of alternative RNA splicing, a process that allows a single gene to produce or code multiple types of protein variants. The discovery, published in the June 27, 2012 issue of Molecular Cell, suggests the new pathway might be a fruitful target for new cancer drugs.

Signal transduction in the cell involves kinases and phosphatases, enzymes that transfer or remove phosphates in protein molecules in a cascade or pathway. SRPK kinases, first described by Xiang-Dong Fu, PhD, professor of cellular and molecular medicine at UC San Diego in 1994, are involved in controlling the activities of splicing regulators in mammalian cells.

Prior studies have implicated SRPK1 in cancer and other human diseases. For example, it has been shown that SRPK1 plays a critical role in regulating the function of Vascular Endothelial Growth Factor or VEGF, which stimulates blood vessel growth in cancer. SRPK1 has been found to be dysregulated in a number of cancers, from kidney and breast to lung and pancreatic.

Conversely, studies suggest the absence of SRPK1 may be problematic as well, at least in terms of controlling some specific cancer phenotypes. Reduced SRPK1, for example, has been linked to drug resistance, a major problem in chemotherapy of cancer.

In their new paper, Fu and colleagues place SRPK1 in a major signal transduction pathway in the cell. "The kinase sits right in the middle of the PI3K-Akt pathway to specifically relay the growth signal to regulate alternative splicing in the nucleus," said Fu. "It's a new signaling branch that has previously escaped detection."

As such, the SRPK offers a new target for disease intervention and treatment, researchers say. "It's a good target because of its central role and because it can be manipulated with compounds that
'/>"/>

Contact: Scott LaFee
slafee@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Enzyme corrects more than 1 million faults in DNA replication
2. Mayo Clinic offers newly approved treatment for acid reflux disease
3. Wilderness Medicine founder offers health tips for summer season
4. Botox Offers Little Relief for Migraine, Study Finds
5. Prosthetic retina offers simple solution to restoring sight
6. Study Offers Ways to Decrease Use of Restraints at Nursing Homes
7. Skin transplant offers new hope for vitiligo patients
8. New molecular structure offers first picture of a protein family vital to human health
9. US Drug Watchdog Launches Now Calls Transvaginal Mesh A Disaster For 100,000's of US Women Recipients And Offers The Names and Contacts Of The Best Women Attorneys
10. SYNERGY HomeCare Offers Free Home Safety Assessments
11. US Drug Watchdog Now Offers To Get A Free Legal Review For All DePuy ASR Recipients Who Received A Letter From Broadspire About Their Recalled DePuy Hip Implant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... , ... September 04, 2015 , ... Having access to ... has led to an increasing amount of unnecessary emergency room visits which affects hospitals’ ... taxes the country’s health bill. Fortunately, a solution to alleviate this problem has recently ...
(Date:9/4/2015)... ... September 04, 2015 , ... Steven Winter Associates, Inc., ... has been selected for the Residential Award of Merit by the Connecticut Green ... Chosen from a highly competitive field of submissions, the net-zero energy residence will ...
(Date:9/4/2015)... ... 2015 , ... FiltersFast.com, the online retail leader in air ... up. FiltersFast.com, will ship all orders over $50.00 for free. Use this ... advantage of this promotion now through September 8, 2015. , Filtersfast.com offers a ...
(Date:9/3/2015)... (PRWEB) , ... September 04, 2015 , ... AlignLife ... of September. , "There are so many children and adults who don't have ... says Dr. Sara Mahalko-Leonhardt. "We love holding our annual Coat Drive to help those ...
(Date:9/3/2015)... ... 2015 , ... TransPack Toon gives users a set of 90 cartoon transitions ... transitions in 30 different styles. Presets range from snow, underwater, forest, futuristic, city and ... Toon features 90 cartoon transitions from 30 unique styles. Editors can choose between ...
Breaking Medicine News(10 mins):Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 2Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 3Health News:South Glastonbury Home Selected for Award by Connecticut Green Building Council 2Health News:FiltersFast.com Wows with a Long Labor Day Weekend Shipping Offer 2Health News:AlignLife is Helping to Keep the Community Warm This Winter 2Health News:Pixel Film Studios Releases TransPack Toon, a New FCPX Transition 2
... these factors influence how likely they are to ... Racial and ethnic variations in how women perceive their ... get screened for cancer, particularly colon cancer, says a ... researchers interviewed 1,160 women, ages 50 to 80, about ...
... In Time For Summer, CINCINNATI, April 15 ... Americans beautify their insides this summer,with the addition of ... lineup. Pink Lemonade joins Berry Burst and Orange flavors ... 100 percent,fiber from psyllium husk making it a delicious ...
... 15 Gentiva Health,Services, Inc. (Nasdaq: GTIV ), ... services, today announced that it has,scheduled a conference call ... 10:00,a.m. ET to discuss operating results for the first ... financial news release the morning of May,1 before pre-market ...
... OF APPROXIMATELY $3.10-$3.20 PER ... DILUTED SHARE, NEW ... pharmaceutical company, today announced that,fully diluted earnings per share (EPS) for the ... share include a,charge of $110,138,000, or $0.35 per share net of tax, ...
... cancer drug Sutent may slow liver cancer progression, scientists ... A new drug duo might help prevent colorectal cancer, ... the progression of liver cancer. , So conclude two ... Research annual meeting in San Diego. , In the ...
... April 15 Wellcorps International, one of,the nations ... a major paper on the history and evolution ... can be found in its entirety at, http://www.wellcorps.com ... Tony Rich and noted,clinical medical anthropologist Meg Jordan, ...
Cached Medicine News:Health News:Women's Awareness of Cancer Risk Linked to Race, Ethnicity 2Health News:Quench Your Summer Thirst...With Fiber 2Health News:Quench Your Summer Thirst...With Fiber 3Health News:Gentiva(R) Health Services Schedules First Quarter Earnings Call and Web Cast for Thursday, May 1, 2008 2Health News:Gentiva(R) Health Services Schedules First Quarter Earnings Call and Web Cast for Thursday, May 1, 2008 3Health News:Forest Laboratories, Inc. Reports Fiscal Year 2008 Fourth Quarter Reported EPS of $0.55 Including $0.35 Per Share Charge for Licensing Payment 2Health News:Forest Laboratories, Inc. Reports Fiscal Year 2008 Fourth Quarter Reported EPS of $0.55 Including $0.35 Per Share Charge for Licensing Payment 3Health News:Forest Laboratories, Inc. Reports Fiscal Year 2008 Fourth Quarter Reported EPS of $0.55 Including $0.35 Per Share Charge for Licensing Payment 4Health News:Forest Laboratories, Inc. Reports Fiscal Year 2008 Fourth Quarter Reported EPS of $0.55 Including $0.35 Per Share Charge for Licensing Payment 5Health News:Forest Laboratories, Inc. Reports Fiscal Year 2008 Fourth Quarter Reported EPS of $0.55 Including $0.35 Per Share Charge for Licensing Payment 6Health News:Forest Laboratories, Inc. Reports Fiscal Year 2008 Fourth Quarter Reported EPS of $0.55 Including $0.35 Per Share Charge for Licensing Payment 7Health News:Forest Laboratories, Inc. Reports Fiscal Year 2008 Fourth Quarter Reported EPS of $0.55 Including $0.35 Per Share Charge for Licensing Payment 8Health News:Forest Laboratories, Inc. Reports Fiscal Year 2008 Fourth Quarter Reported EPS of $0.55 Including $0.35 Per Share Charge for Licensing Payment 9Health News:New Drug Duo Helps Fight Colon Cancer 2Health News:New Drug Duo Helps Fight Colon Cancer 3Health News:New Drug Duo Helps Fight Colon Cancer 4Health News:Wellcorps International Releases Major Paper on History and Evolution of Amphetamine and Anti-Depressant Use in America 2
(Date:9/4/2015)... 2015  Janssen Research & Development, LLC (Janssen) ... (FDA) has accepted for Priority Review the Biologics ... for patients with multiple myeloma who are refractory ... immunomodulatory agent (IMiD), or who have received three ... PI and an IMiD. This is referred to ...
(Date:9/4/2015)... DALLAS , Sept. 4, 2015  Essilor is ... glasses, millennials, greatest defense against the eyestrain that comes ... are intended to serve as an everyday pair of ... of people who are on smart phones, tablets and ... only benefit those who require a prescription but also ...
(Date:9/4/2015)... , Sept. 4, 2015  PTC Therapeutics, Inc. ... five recipients of its first-ever global awards program, ... and Empowerment), designed to aid nonprofit organizations that ... (DMD) community. The announcement is made as the ... Duchenne Awareness Day on Monday, September 7, 2015. ...
Breaking Medicine Technology:U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 2U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 3U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 4U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 5U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 6U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 7Essilor Launches New Eyezen Glasses Specifically Designed For A Digital Focused Audience 2PTC Therapeutics Announces Five Winners In Its First-ever Global Duchenne Muscular Dystrophy Patient Group Award 2PTC Therapeutics Announces Five Winners In Its First-ever Global Duchenne Muscular Dystrophy Patient Group Award 3PTC Therapeutics Announces Five Winners In Its First-ever Global Duchenne Muscular Dystrophy Patient Group Award 4
Custom Conjugation Services...
Colloidal Gold Conjugated, Streptavidin - 50 OD...
Colloidal Gold Conjugated, Goat anti-rabbit IgG (H&L) - 12 OD...
Colloidal Gold Conjugated, Goat anti-mouse IgG (H&L) - 50 OD...
Medicine Products: